The Society of Nuclear Medicine and Molecular Imaging (SNMMI) highlighted research on a newly developed targeted radiopharmaceutical treatment that can effectively slow tumor growth in pancreatic ductal adenocarcinoma (PDAC).
“PDAC accounts for over 90% of pancreatic cancer cases and remains one of the most lethal malignancies, with a five-year survival rate of less than five percent in patients with metastatic disease,” SNMMI said, in a May 13 news release.
Biodistribution of Lu-177 AKIR001. (A) Mice (N = 12) bearing BxPC3 tumors were injected with Lu-177 AKIR001 and dissected at 24 (N = 4), 96 (N = 4), and 168 hours (N = 4) postinjection. Error bars represent SD. (B) Representative SPECT/CT images at 96 hours postinjection. GI = gastrointestinal.SNMMI
"Targeted radiotherapies have already transformed treatment for prostate and neuroendocrine tumors," said senior author Marika Nestor, PhD, of Uppsala University in Sweden. "Our findings suggest that CD44v6 can be added to the list of targets that can be reached with this approach, and, importantly in a cancer where we desperately need new options."
The full study is available in the April issue of the Journal of Nuclear Medicine.
